Nama's AI scorecard currently rates Regeneron Pharmaceuticals Buy (7.8 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.

What is REGN's P/E ratio?

Regeneron Pharmaceuticals trades at a trailing price-to-earnings ratio of 16.4.

When does REGN report earnings?

Regeneron Pharmaceuticals's next scheduled report is on Jan 28, 2027. Analysts expect EPS of $25.30.

What is the REGN price target?

The median analyst price target from 27 analysts is $982.00, with a range of $812.00 – $1,175.00.

Is REGN Shariah compliant?

Nama's AAOIFI-style screen reads Regeneron Pharmaceuticals as Shariah Compliant. Passes our debt, cash and income screen; not a scholar's ruling.

Does REGN pay a dividend?

Yes — Regeneron Pharmaceuticals's dividend yield is 0.4%.

Nama Insights

Regeneron Pharmaceuticals (REGN)

Healthcare · Biotechnology · NASDAQ

S&P 500Nasdaq-100

Regeneron Pharmaceuticals (REGN) is a Healthcare company in the Biotechnology industry. It has a market capitalization of $93.55B, a trailing price-to-earnings ratio of 16.4 and a free-cash-flow yield of 3.8%. Over the most recent reported fiscal year, revenue grew 1.0% and free cash flow per share grew 12.8%. Nama's AI scorecard rates it Buy, 7.8 out of 10. On 12-month momentum it ranks in the middle band of its market.

AI scorecard

Buy · 7.8/10

Clearly positive, short of the top band. As of Nov 7, 2026.

Momentum

Middle · +14.7% over 12 months ex. last

Middle fifth of its market on the past year's move.

Shariah screen

Shariah Compliant

Passes our debt, cash and income screen; not a scholar's ruling.

Off its high

-25.3%

How far the last close sits under the highest price of the past five years.

Market cap	$93.55B
Trailing P/E	16.4
Price / book	2.9
Price / sales	5.5
FCF yield	3.8%
Dividend yield	0.4%
Gross margin	84.9%
Operating margin	26.9%
Net margin	27.9%
Revenue growth (YoY)	+1.0%
Revenue growth (3-yr annual)	+5.6%
EPS growth (YoY)	-2.8%
FCF/share growth (YoY)	+12.8%
Beta	0.1
Exchange	NASDAQ
Sector	Healthcare
Industry	Biotechnology

REGN earnings

Next report: Jan 28, 2027 (Q4 2026, EPS estimate $25.30). Beat the EPS estimate in 4 of 4 recent quarters.

Quarter	Reported	EPS	Estimate	Surprise	Revenue
Q3 2026	Oct 30, 2026	$20.07	$16.25	+23.5%	$5.12B
Q2 2026	Jul 30, 2026	$14.29	$10.21	+40.0%	$4.29B
Q1 2026	Apr 29, 2026	$9.47	$8.90	+6.4%	$3.61B
Q4 2025	Jan 30, 2026	$11.44	$10.75	+6.4%	$3.88B

REGN analyst price target

Median target $982.00 from 27 analysts, ranging $812.00 – $1,175.00.

Biotechnology peers

Ticker	Company	Market cap	P/E
VRTX	Vertex Pharmaceuticals	$138.71B	28.8
MRNA	Moderna	$101.48B	—
ARGX	argenx	$58.31B	32.4
ONC	BeOne Medicines	$46.30B	51.7
RVMD	Revolution Medicines	$41.59B	—
RPRX	Royalty Pharma	$38.70B	12.7
GMAB	Genmab A/S	$32.98B	38.9
ROIV	Roivant Sciences	$28.08B	—

Explore live REGN data on Nama Insights →

Recent Congressional trades

Regeneron Pharmaceuticals trades disclosed by members of the US House and Senate under the STOCK Act. See the full Congress trades board →

Member	Chamber	Trade	Amount	Disclosed
Alan Armstrong	Senate	Buy	$1,001 - $15,000	Jul 21, 2026
Gilbert Cisneros	House	Sell	$1,001 - $15,000	Jun 8, 2026
Julia Letlow	House	Buy	$1,001 - $15,000	Mar 12, 2026
Gilbert Cisneros	House	Buy	$1,001 - $15,000	Dec 15, 2025
Rob Bresnahan	House	Buy	$1,001 - $15,000	Jun 9, 2025
Byron Donalds	House	Sell	$1,001 - $15,000	May 24, 2025
Byron Donalds	House	Sell	$1,001 - $15,000	May 24, 2025
Julie Johnson	House	Sell	$1,001 - $15,000	May 14, 2025
Rob Bresnahan	House	Sell	$1,001 - $15,000	May 8, 2025
Jefferson Shreve	House	Sell	$15,001 - $50,000	May 8, 2025
Rob Bresnahan	House	Sell	$1,001 - $15,000	Mar 27, 2025
Julie Johnson	House	Sell	$1,001 - $15,000	Mar 12, 2025

REGN FAQ

Is REGN a buy?: Nama's AI scorecard currently rates Regeneron Pharmaceuticals Buy (7.8 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
What is REGN's P/E ratio?: Regeneron Pharmaceuticals trades at a trailing price-to-earnings ratio of 16.4.
When does REGN report earnings?: Regeneron Pharmaceuticals's next scheduled report is on Jan 28, 2027. Analysts expect EPS of $25.30.
What is the REGN price target?: The median analyst price target from 27 analysts is $982.00, with a range of $812.00 – $1,175.00.
Is REGN Shariah compliant?: Nama's AAOIFI-style screen reads Regeneron Pharmaceuticals as Shariah Compliant. Passes our debt, cash and income screen; not a scholar's ruling.
Does REGN pay a dividend?: Yes — Regeneron Pharmaceuticals's dividend yield is 0.4%.